Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

NCT05310591 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

B Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, in Relapse

Interventions

DRUG: Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )
DRUG: Nivolumab starting at day -1

Sponsor

Assistance Publique - Hôpitaux de Paris